Kyntra Bio returns to profit in Q3 as revenue rises

By Reuters News


Overview

  • Rare disease biopharmaceutical's Q3 revenue from continuing operations rose yr/yr

  • Net income from continuing operations for Q3 was $0.2 mln, reversing a loss last yr

  • Company completed royalty financing agreement restructuring, reducing payment obligations by $60 mln


Outlook

  • Company plans to start Phase 3 roxadustat trial in 1Q 2027, pending partnership or capital raise

  • Kyntra Bio expects to reduce operating expenses by over $20 mln in 2027 and 2028

  • Company expects cash and equivalents to fund operations into 2028


Result Drivers

  • PROGRAM TERMINATIONS - Co discontinued development of FG-3246 and FG-3180 after interim analysis showed insufficient efficacy, resulting in expected operating expense reductions over $20 mln in 2027 and 2028

  • ROYALTY AGREEMENT RESTRUCTURING - Co restructured royalty financing agreement, reducing maximum aggregate payment obligation by $60 mln, leaving only $15 mln in future royalty-backed payments

  • PIPELINE FOCUS - Co said it is focusing on rare disease portfolio, planning a pivotal Phase 3 trial for roxadustat in LR-MDS patients, subject to partnership or capital raise


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Income

$157,000

Q3 Net Income from Cont Ops

$157,000

Q3 Revenue from Cont Ops

$1.76 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Kyntra Bio, Inc. is $38.00, about 1,004.7% above its November 13 closing price of $3.44


Reuters Recommended Reads

  • Nov 13 - Canada's IM Cannabis Q3 revenue falls sharply, net loss widens

  • Nov 16 - Rhythm drug shows sustained weight reduction in patients with brain damage-related obesity

  • Nov 16 - Canada's Helus Pharma Q2 net loss widens on higher operating expenses


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.